NEW YORK, April 24 - Genaissance Pharmaceuticals said Tuesday it had begun enrolling patients for its clinical trials which will aim to correlate haplotypes with individuals’ reactions to particular drugs.

In its initial study, the company plans to enroll about 600 patients at 60 medical centers in the US to correlate patient haplotypes with the affects of cholesterol lowering drugs. The Statin Response Examined by Genetic HAP Study, or STRENGTH, will look at Lipitor, Zocor, Pravachol, and Baycol. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.